Difficult to assess how the scoping study, which I personally expect to be published within the next 2 weeks, will affect the course.
The mood for metals is bad at the moment. We will also have to wait and see how the identified issues develop in December in terms of resumption of operations, the challenges of shipping and reaching Nameplate Production.The quarterly loss of AUD 5 MILLION was a real shock, from which E25 has not yet recovered.
I would therefore not set the expectations with regard to the scoping study too high.
- Forums
- ASX - By Stock
- Scoping Study
E25
element 25 limited
Add to My Watchlist
0.00%
!
22.5¢

Difficult to assess how the scoping study, which I personally...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.43M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $21.94K | 100.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 62609 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 0.215 |
3 | 28857 | 0.210 |
2 | 8107 | 0.205 |
7 | 59405 | 0.200 |
3 | 13077 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 62609 | 2 |
0.230 | 72958 | 1 |
0.235 | 24800 | 2 |
0.240 | 252084 | 2 |
0.245 | 21276 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online